SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shib2's story is nothing short of extraordinary, a tale of mystery, transformation, unity, and the unwavering determination of its community.  The Enigmatic Origins  Shib2 was born from the vision of a reclusive developer, known only by the pseudonym "Cipher." Unlike many cryptocurrency projects that begin with a whitepaper and a team of experts, Shib2 emerged quietly and mysteriously. Cipher, shrouded in anonymity, released the project's smart contract on the Ethereum blockchain with little fanfare. There were no pre-sales, no flashy marketing campaigns – just a single post on a cryptocurrency forum.  A Humble Beginning  In the early days, Shib2 was nothing more than a curiosity. Its smart contract was simple, allowing users to exchange Ethereum for Shib2 tokens. The project lacked a clear roadmap or a well-defined purpose, leaving many in the crypto community skeptical. Yet, something about Shib2 intrigued a small group of early adopters who saw its potential.  The Power of Community  What truly sets Shib2 apart is its community. As more people discovered the project, they formed a tight-knit group of enthusiasts. They began discussing its possibilities, proposing ideas, and volunteering their skills to help the project grow. Shib2 was no longer just Cipher's creation; it had become a collective endeavor.  Innovation and Transformation  The early days of Shib2 were marked by a rapid evolution. The community, driven by a desire to make Shib2 more than just a simple token, started developing new features and use cases. They introduced decentralized applications (dApps) that utilized Shib2, ranging from decentralized exchanges to governance platforms.  One of the project's standout features was the Shib2 NFT marketplace, where artists and creators could mint and trade non-fungible tokens. This marketplace quickly gained traction and became a hub for digital artists looking to explore the blockchain space.  Challenges and Growth  Of course, Shib2's journey was not without its challenges. The project faced its fair share of security issues and technical hurdles. Yet, the community's resilience shone through as they collectively tackled these obstacles. Audits were conducted, developers collaborated, and improvements were made. Shib2's journey was marked by a relentless pursuit of innovation and security.  Shib2 Today  Today, Shib2 stands as a testament to the power of community-driven projects. It has grown beyond anyone's expectations, boasting a thriving ecosystem of dApps, a robust NFT marketplace, and a dedicated community that continues to push the boundaries of what is possible in the world of blockchain technology.  Cipher, the enigmatic founder, still remains elusive, but their creation, Shib2, has taken on a life of its own. It has become a symbol of the potential for innovation, transformation, and unity within the cryptocurrency space.

SHIB2.0

SHIB2 is trending as community members discuss its volatile price action and potential for high rewards, with some comparing it to the original SHIB. Some users are talking about accumulating more while it's still early, viewing it as a second chance to capture the gains of its predecessor. The coin's increasing number of holders and growing market capitalization are also being highlighted.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is gaining attention as a Solana-based memecoin with a growing community and potential utility, sparking discussions about its long-term prospects. Community members highlight the project's consistent development, low market cap, and upcoming announcements as reasons for their bullish sentiment. Some traders are comparing it to other successful memecoins on $SOL, while others are taking note of its trending status on social platforms.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

ORCA CRYPTO is trending as traders discuss recent integrations and a DAO-approved buyback program aimed at reducing supply and stabilizing price. Community members are weighing in on short positions and potential run-ups, while also pointing to anti-bot measures. Bullish sentiment seems to be building with some eyeing longer-term targets amid increasing trading volume.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF ($DAX) is trending due to technical analysis suggesting strong buying opportunities and reactions at specific price levels, particularly around a "Blue Box" area. Community discussions revolve around the Elliott Wave theory and potential moves based on these technical indicators. Despite some concerns about economic growth, particularly in Germany, the ETF has recently hit new highs, bolstering bullish sentiment.

Harvest automatically farms the highest yields in DeFi

Harvest Finance

Harvest Finance ($FARM) is gaining attention as traders note its low circulating supply and potential for significant price movement. Community members are discussing technical indicators suggesting a possible breakout, with some anticipating a rapid surge. The recent Arbitrum DAO approval for yield farming incentives is also a key point of interest for the coin.

Targa Resources Corp. engages in the business of gathering, compressing, treating, processing, transporting, and purchasing and selling natural gas. It operates through the following segments: Gathering and Processing, and Logistics and Transportation, and Other. The Gathering and Processing segment includes assets used in the gathering, and purchase and sale of natural gas produced from oil and gas wells. The Logistics and Transportation segment refers to the activities and assets necessary to convert mixed natural gas liquids (NGLs) into NGL products. The Other contains the results of commodity derivative activity mark-to-market gains and losses related to derivative contracts. The company was founded on October 27, 2005 and is headquartered in Houston, TX.

Targa Resources Corp

Targa Resources is trending as analysts adjust price targets and ratings, with many setting 'Outperform' or 'Buy' ratings, reflecting confidence in the company's growth. Community discussions also highlight the company's pipeline projects and strength in the energy sector. Some investors are closely watching for potential entry points following recent price movements, while others discuss the implications of insider selling.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending as the community anticipates a marketing announcement and discusses potential integration with Elon Musk's ventures, sparking excitement about a possible surge. Traders are analyzing Floki's structure and potential for a squeeze, while some express frustration with recent price action. Community members also highlight the trading bot and staking rewards.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending due to community excitement around its potential as foundational infrastructure for TradFi, emphasized by its high throughput and compliance-aware design. Investors are actively discussing the token's value proposition in comparison to major platforms like Amazon, Google, and Microsoft, viewing KTA as a targeted bet on the future of financial plumbing. The community also highlights potential partnerships, particularly with Stripe, as a key catalyst.

VanEck ETF Trust - VanEck Steel ETF

VanEck Steel ETF

The VanEck Steel ETF ($SLX) is trending amid discussions of infrastructure spending and rising steel prices, with community members pointing to technical patterns and potential breakouts. Bullish sentiment is fueled by expectations of continued strong demand and tight supply in the steel market. Concerns about global overcapacity and potential pullbacks are also being actively debated.

Crexendo, Inc. engages in the provision of telecommunications services, broadband Internet services, and other cloud business services. It operates through the Cloud Telecommunications Services and Software Solutions segments. The Cloud Telecommunications Services segment focuses on selling cloud telecommunication products and services and broadband Internet services. The software solutions segment focuses on software licenses, software maintenance support and professional services. The company was founded on April 13, 1995 and is headquartered in Tempe, AZ.

Crexendo Inc

CXDO is trending due to positive sentiment around potential market share gains from competitors and anticipation of continued growth, with the community actively discussing analyst upgrades and price targets.  Recent earnings reports and strategic partnerships are also fueling optimism, with some seeing a strong long-term growth trajectory. Chatter suggests institutions are accumulating shares, potentially driving the price higher.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus Pharmaceuticals, representing an 8.5% downside from the last close.The research firm maintained a 'Neutral' rating on the stock.Last week, Supernus said it would acquire Sage for $8.5 per share in cash, plus a contingent value right (CVR) worth up to $3.5, based on commercial milestones for Zurzuvae, an FDA-approved treatment for postpartum depression co-developed with Biogen.&nbsp;The total transaction value of up to $12 per share reflects a 79% premium to Sage’s last closing price before the announcement.The deal, expected to close in the third quarter of 2025, is intended to expand Supernus’ neuropsychiatry portfolio and&nbsp;could reduce annual costs by up to&nbsp;$200 million.The company also guaranteed a cash payout at closing, excluding value from the CVR, which remains contingent on future sales performance.&nbsp;Several other firms adjusted their price targets in response to the Supernus deal: Piper Sandler lowered its target to $8.50 from $9,&nbsp;while Truist raised its target to $9 from $8&nbsp;and Canaccord increased its target to $8.50 from $8, each maintaining a ‘Hold’ or ‘Neutral’ rating.&nbsp;BofA removed its rating altogether, stating that Sage shares are no longer trading on fundamentals following the acquisition announcement.H.C. Wainwright noted the $22.4 million breakup fee may not be large enough to prevent a competing offer, particularly from Biogen, which already co-commercializes Zurzuvae with Sage in the U.S.In January, Sage Therapeutics’ board&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-gains-onfda-nod-for-leqembi-dosing/chblEfgRYE">unanimously rejected</a> Biogen's unsolicited offer to acquire all outstanding shares for $7.22 per share.&nbsp;The company said the offer “significantly undervalued” Sage and was not in the best interest of shareholders.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Shares of Sage Therapeutics closed up 1.9% at $9.3 on Friday. The stock has risen 60.9% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Equity

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening">acquire</a> Sage Therapeutics, Inc. (SAGE) for up to $795 million. SAGE stock traded 34% higher on Monday morning following the announcement.Under the terms of the deal, Supernus intends to acquire Sage for a total consideration of $12 per share in cash, including $8.50 per share payable at closing and a contingent value right (CVR) worth up to $3.50 per share in cash. The CVR is payable upon achieving certain net sales and commercial milestones, the companies said.The total consideration represents a premium of about 79% from SAGE’s closing price of $6.7 on Friday.The transaction is expected to close in the third quarter of 2025 and strengthen Supernus’ neuropsychiatry portfolio with the addition of Zurzuvae, the only oral medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with postpartum depression.Zurzuvae was co-developed by Sage and Biogen, Inc. (BIIB). Through a collaboration agreement with Biogen, Supernus will report collaboration revenue that is 50% of the total net revenue Biogen records for Zurzuvae in the U.S.In 2024 alone, Sage recorded a collaboration revenue of $36.1 million from net sales of Zurzuvae.Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, Onapgo, and Gocovri.The acquisition is also expected to be significantly accretive in 2026, with cost synergies of up to $200 million on an annual basis, the companies said.On Stocktwits, retail sentiment around SUPN jumped from ‘neutral’ to ‘bullish territory over the past 24 hours, while chatter increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_18_03_AM_png_8f57b78080.webp" alt="Screenshot 2025-06-16 at 10.18.03 AM.png" width="625" height="68"><figcaption>SUPN's Sentiment Meter and Message Volume as of 10:15 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around SAGE increased from ‘neutral’ to ‘extremely bullish’ territory while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_24_57_AM_png_4d871e71b4.webp" alt="Screenshot 2025-06-16 at 10.24.57 AM.png" width="628" height="67"><figcaption>SAGE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>This year, <a href="https://stocktwits.com/symbol/SAGE">SAGE stock</a> has risen 56% while <a href="https://stocktwits.com/symbol/SUPN">SUPN stock</a> fell about 10%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-organization-enters-telecom-market-touts-us-made-phone/chlntPmRRR8">Trump Organization Enters Telecom Market, Touts US-Made Phone Amid President’s Push To Reshore Smartphone Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results...

Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered fallout from a rejected acquisition proposal.Sage Therapeutics announced its board had unanimously rejected Biogen's unsolicited Jan. 10&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sage-stock-soars-on-biogen-bid/chGN0nXRNV">offer</a> to acquire all outstanding Sage shares for $7.22 per share.&nbsp;The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.Sage's board also revealed plans to explore strategic alternatives, cautioning that a transaction is not guaranteed.&nbsp;Meanwhile, Sage reaffirmed its commitment to establishing Zurzuvae as the standard treatment for postpartum depression.&nbsp;Biogen, which co-markets Zurzuvae, had argued that full ownership would aid its rollout but expressed little interest in Sage's broader pipeline when it placed its bid.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BIIB_sentiment_and_message_volume_Jan_27_d1b89b799f.png" alt="BIIB sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>BIIB sentiment and message volume Jan 27 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Following the rejection, retail sentiment for Biogen turned 'bearish' on Stocktwits, with increased message volume reflecting investor concerns about the deal's implications.<stembedurl>https://stocktwits.com/Gito/message/601644664</stembedurl><stembedurl>https://stocktwits.com/Scanners_Free/message/601610361</stembedurl>However, Biogen received a significant boost as the FDA on Sunday approved a supplemental biologics license application for Leqembi, developed in collaboration with Eisai Co. Ltd.&nbsp;The new label allows for once-every-four-weeks intravenous maintenance dosing following an 18-month initiation phase of biweekly treatments.Leqembi, used to treat early-stage Alzheimer's disease, addresses patients with mild cognitive impairment or mild dementia.&nbsp;The updated dosing regimen is expected to improve patient compliance while enhancing convenience.However, Biogen's challenges remain stark; the stock has lost nearly 40% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogens Unsolicited Acquisition Proposal

Sage Therapeutics, Inc. (Nasdaq: SAGE) (Sage or the Company), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board intends...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Sage Therapeutics Inc

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

SAGE
Sage Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SAGE News

SAGESage Therapeutics Inc